ArticleRedox report : communications in free radical research2026
Artesunate ameliorates experimental autoimmune uveitis by inhibiting the LCN2-STAT3 axis and suppressing microglial activation.
Article in Redox report : communications in free radical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issuedCorrection.2026
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and underlying molecular mechanisms of artesunate (ART) in experimental autoimmune uveitis (EAU).
methodsAn EAU mouse model was established and treated with ART via oral gavage. Disease severity was assessed by clinical scoring and retinal histology. SPR analysis examined ART binding to LCN2 and STAT3. Immunofluorescence co-staining was conducted to evaluate the expression and co-localization of LCN2 with microglia in retinal tissues. Western blot analysis was performed to measure protein levels of STAT3, LCN2, SLC7A11, FTH1, GPX4, IL-6, IL-1β, IL17A and TNF-α. In vitro, BV2 microglial cells were used, and LCN2 was knocked down with siRNA. Inflammatory cytokine concentrations in retina and BV2 cell culture supernatants were assessed through ELISA.
resultsART treatment significantly improved clinical and histopathological scores in EAU mice and exhibited moderate binding affinity for LCN2 and STAT3. It suppressed microglial activation and downregulated the expression of LCN2 and STAT3, along with the release of IL-6, IL-1β, IL17A and TNF-α. In BV2 microglial cells, ART decreased LCN2 expression and attenuated proinflammatory cytokine secretion.
conclusionsArtesunate attenuates EAU by inhibiting the LCN2-STAT3 axis and suppressing the activation of microglial and Th17 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.